• S&P 500: 1,340.92
  • Change: -0.82%
$2.96 -0.12 (-3.90%)
2/10/2012 10:32 AM

Corcept Therapeutics, Inc. (NASDAQ:CORT)

CAPS Rating: 2 out of 5

A pharmaceutical company which is engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases.

Current Price $2.96 Mkt Cap $249.24M
Open $3.05 P/E Ratio 0.00
Prev. Close $3.08 Div. (Yield) N/A (N/A)
Daily Range $2.85 - $3.05 Volume 182,189
52-Wk Range $2.51 - $5.07 Avg. Daily Vol. 0

News & Discussion Boards

Caps

How do you think CORT will perform against the market?

You must Sign in to MSN Caps before you can make a call.

All Players

61 Outperform
22 Underperform
 

All-Star Players

13 Outperform
4 Underperform
 

Wall Street

1 Outperform
1 Underperform
 

Top CORT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.32)
Submitted September 23, 2011

For once I seem to have gotten lucky with a red thumb. I predicted incorrectly that the phase III study of Corlux in Cushing's disease would be a failure, given the prior failure of the drug for several other indications. The company ultimately… More

Add Comment | Reply | Report this Post

zzlangerhans (99.32)
Submitted January 26, 2012

The time has come to take a position on Corcept in advance of the February 17 PDUFA for Corlux for Cushing's syndrome. Needless to say, I'm predicting a Complete Response letter. If I'm wrong, I'll lose my hard fought score leadership for Corcept,… More

Add Comment | Reply | Report this Post
CORT VS S&P 500 (SPY)

Fools bullish on CORT are also bullish on:

Fools bearish on CORT are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about CORT.

Recs

0
Member Avatar Teknowizz (98.20) Submitted: 2/3/2012 2:29:45 PM : Outperform Start Price: $3.40 CORT Score: -12.70

PUDFA for Korlym for Cushings on Feb 17th. Given that the FDA has indicated that no REMS program is required (Risk Evaluation and Mitigation Strategy) one may expect approval.
Altough a very rare disease, CORT can use the money, so expecting a pop when approved.

Report this Post 1 Comment | Reply | Permalink

Recs

0
Member Avatar Shankapotamus (< 20) Submitted: 2/2/2012 3:22:41 PM : Outperform Start Price: $3.28 CORT Score: -9.53

FDA catalyst play

Report this Post Add Comment | Reply | Permalink

Recs

0
Member Avatar bassettt (65.96) Submitted: 7/1/2011 11:44:33 PM : Underperform Start Price: $3.92 CORT Score: +24.74

This stock may be a worth less than 50 cents in a year. The drug the FDA is currently reviewing, Corlux, has the same active ingredient as the pill that is taken to eliminate early pregnancy. I don't see the FDA allowing such a drug to be distributed when Corlux would only benefit about 5-10 thousand people anyway. The rest of their pipeline is dependent on the same active ingredient.

Report this Post Add Comment | Reply | Permalink
View All 9 Pitches »

Leaderboard

Find the members with the highest scoring picks in CORT.

Score Leader

zzlangerhans

zzlangerhans (99.32) Score: +115.98

I'm back in the saddle again on Corcept. Will I get thrown off or widen my lead? But shhh, let's watch ...

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		Index
Gain 		Score Commentary
Okcfirefighter < 20 12/17/2010 Underperform 5Y $4.30 -31.16% +7.81% +38.98 0 Comment
ugrmdclr 26.54 7/21/2008 Outperform NS $2.15 +37.67% +9.38% +28.29 0 Comment
LICASTICK 51.59 9/10/2010 Underperform NS $3.20 -7.50% +20.34% +27.84 0 Comment
bassettt 65.96 7/5/2011 Underperform 1Y $3.92 -24.49% +0.25% +24.74 1 Comment
beugster < 20 4/3/2008 Underperform 3W $3.80 -22.11% +2.26% +24.36 0 Comment
jcook79 99.13 8/11/2008 Outperform NS $2.30 +28.70% +6.04% +22.65 0 Comment
Jgleason78 84.54 4/2/2008 7/24/2008 Underperform 3M $3.74 -20.86% +1.24% +22.10 0 Comment
william19d 89.00 11/24/2009 Outperform 5Y $2.07 +43.00% +21.02% +21.97 0 Comment
hedgefund51 < 20 1/13/2010 Underperform NS $3.03 -2.31% +17.69% +20.00 0 Comment
Stoxter 72.77 10/15/2007 Underperform 1Y $4.18 -29.19% -10.09% +19.10 0 Comment
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackBioLogicEqu 62.41 1/5/2012 Underperform NS $3.38 -12.43% +5.59% +18.02 0 Comment
TrackLadenburg 78.38 1/6/2010 Outperform NS $2.99 -1.00% +18.14% -19.14 0 Comment
TrackTWeisel 91.99 8/15/2006 Outperform NS $3.69 -100.00% +1.93% -101.93 8/25/2006 @ $0.00 0 Comment

Featured Broker Partners